Re: Farmas USA
ACHN
Le caen 15 milloncejos de JNJ. Buenos son.
Achillion Announces Clinical Milestone for the Advancement of JNJ-4178 in Phase 2B Development for Chronic HCV
ACHN
Le caen 15 milloncejos de JNJ. Buenos son.
Achillion Announces Clinical Milestone for the Advancement of JNJ-4178 in Phase 2B Development for Chronic HCV
CNAT cerró con +34% pese intento de corto/cubrir cortos del bastardo incluido.
Summary
Dr. Tom Price will be nominated to be Secretary of Health and Human Services.
Dr. Price favors a free-market approach to the biotechnology industry.
The status quo for pricing drugs will largely be maintained.
Biotech stock prices may rise as fears of price controls evaporate.
http://seekingalpha.com/article/4032882-tom-price-appointment-bodes-well-biotech-2017
4ª semana consecutiva marcando 9,00 como techo ... a ver que pasa en la 5ª que sera la primera del proximo año ...
ARRY
ADXS
BD, ayer vendi la mitad de la posición a 7,90. Supongo que sería el paquete que compre a 7,85 por los datos que me ha dado bankinter. Me quedan 3 a 7,50; 7,30 y 7,20.
En PM con 100 cromos la han tirado a 7,25. A ver como respira hoy esto.
Espero que no haya pillado a nadie ...
ANTH -66%
http://www.marketwatch.com/story/anthera-pharma-plunges-66-after-missing-target-in-study-2016-12-27
GALE + 60 %
.........?
--
Why You Should (and Shouldn't) Buy Galena Biopharma, Inc
http://www.fool.com/investing/2016/12/05/why-you-should-and-shouldnt-buy-galena-biopharma-i.aspx
GALE-401 drug enter phase 3
GALE